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Abstract
There is an epidemic of nonalcoholic fatty liver disease (NAFLD) paralleling the 
epidemic of obesity and metabolic syndrome. NAFLD is the most common cause of 
abnormal liver function test and chronic liver disease in the Western world. NAFLD 
can progress to nonalcoholic steatohepatitis, cirrhosis of the liver, and hepatocel-
lular carcinoma. Most patients with NAFLD die from cardiovascular disease and 
malignancy. Medical therapy for NAFLD is not very effective at the present time. 
Treatment of NAFLD starts with weight loss. Bariatric surgery is able to cause sig-
nificant and sustained weight loss. There are different models of bariatric surgery. 
Commonly performed ones are Roux-en-Y gastric bypass (RYGB), sleeve gastrec-
tomy, and laparoscopic adjustable gastric banding (LAGB). They can improve 
steatosis, steatohepatitis, and fibrosis in non-cirrhotic and compensated cirrhotic 
patients. Each of them has benefits and risks. The bariatric surgical procedures need 
to be individualized according to the patient’s condition.
Keywords: nonalcoholic fatty liver disease, bariatric surgery, role of surgery in 
NAFLD, liver transplantation and NAFLD
1. Introduction
There is a tremendous rise in the prevalence of nonalcoholic fatty liver disease 
(NAFLD) throughout the world [1]. About 20% of the world population suffer 
from NAFLD [2]. NAFLD is the most common cause of chronic liver disease in the 
developed countries. In the United States, it is the second most common indication 
of liver transplantation. It affects all age groups and ethnicities [3]. The epidemic 
of NAFLD parallels the epidemic of obesity and metabolic syndrome in the world. 
In fact, most (80%) of the patients suffering from NAFLD are overweight [4], and 
85% of morbidly obese individuals with body mass index (BMI) >40 have NAFLD 
[5]. As the disease is related to insulin resistance, 70% of non-insulin-dependent 
diabetic patients suffer from NAFLD [6]. The disease starts with benign revers-
ible macrovesicular steatosis affecting more than 5% of the hepatocytes. Then it 
progresses to nonalcoholic steatohepatitis (NASH), steatofibrosis, cirrhosis of the 
liver, liver failure, and hepatocellular carcinoma [7]. Weight loss, pharmacologi-
cal intervention, and bariatric surgery are the three main modes of therapy of 
NAFLD. Weight loss by diet, exercise, and lifestyle modification is the first-line 
treatment of NAFLD. There are few pharmacologic agents available for the treat-
ment of NAFLD. But as it is difficult to lose weight and maintain targeted body 
weight by lifestyle modifications, and pharmacological interventions are not 
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that successful, there is a potential role of bariatric surgery in the treatment of 
NAFLD. In this chapter, we will be discussing the indications and types of bariatric 
surgery as well as their benefits and risks.
At the present time, bariatric surgery is indicated only for morbidly obese 
individuals. The American Society for Metabolic and Bariatric Surgery (ASMBS) 
recommends bariatric surgery for individuals who have BMI of ≥40 or ≥35 plus at 
least one or more obesity-related complications (type II diabetes mellitus, hyper-
tension, hyperlipidemia, obstructive sleep apnea, nonalcoholic fatty liver disease, 
gastrointestinal disorders, osteoarthritis, heart disease) and have failed to achieve 
targeted weight loss despite diet and exercise [8]. The American Association for 
the Study of Liver Diseases (AASLD) recommends to consider bariatric surgery in 
otherwise obese individuals with NALFD or NASH.
Bariatric surgery is able to achieve severe (40–71%) weight loss and improve 
insulin resistance and obesity-related metabolic complications [9]. There are many 
studies showing the benefits of weight loss in NAFLD following bariatric surgery. 
But at the present time, there is no large randomized control trial evaluating the 
effects of bariatric surgery in NAFLD.
Bariatric surgical procedures are classified into three broad categories on the 
basis of their mechanism of action [10]:
1. Restrictive procedures: The size of the stomach is surgically reduced, and as a 
result, the food intake is diminished. These procedures include sleeve gas-
trectomy, laparoscopic adjustable gastric banding (LAGB), and vertical band 
gastroplasty (not done anymore because of high complication rate and diffi-
culty in maintaining weight loss). In sleeve gastrectomy (Figure 1), the gastric 
fundus and greater curvature of the stomach are resected vertically (>80% of 
the stomach is removed) making the stomach tubular (like a banana) with less 
capacity (initial filling volume of <100 ml) and less stretchy with rapid gastric 
emptying. Feeling of hunger is reduced because of resection of fundus con-
taining ghrelinergic cells [11]. In LAGB (Figure 2), an adjustable and inflatable 
silicone band is placed around the upper stomach dividing the stomach into 
two compartments: a proximal small gastric pouch (20–30 ml volume) and 
Figure 1. 
Sleeve gastrectomy.
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a distal larger residual stomach. The size of the opening between the gastric 
pouch and the residual stomach can be adjusted as the band is connected to a 
subcutaneous infusion port [12].
2. Malabsorptive procedures: A long segment of the small intestine is bypassed, 
and as a result, the digestive juices digest the food in the distal part of the 
small intestine, and malabsorption of food occurs. These procedures include 
biliopancreatic diversion with duodenal switch (Figure 3) and biliopancreatic 
diversion (Figure 4).
In biliopancreatic diversion (BPD) with duodenal switch (DS), the stomach size 
is first reduced by doing a partial sleeve gastrectomy and preserving the pylorus. 
Then the first part of the duodenum is divided distal to the pylorus. The distal 
Figure 2. 
LAGB.
Figure 3. 
BPD with duodenal switch.
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end of the duodenum is closed. The jejunum is then divided 250 cm proximal 
to the ileocecal valve. The distal end of the jejunum is then anastomosed to 
the proximal end of the duodenum creating a duodenojejunostomy (duodenal 
switch). The proximal end of the jejunum is then attached to the ileum 100 cm 
proximal to the ileocecal valve. As a result, there is restriction of food intake due 
to gastric sleeve, and most of the small intestine is bypassed leading to malab-
sorption of nutrients. The biliary pancreatic limb carries biliary and pancreatic 
secretions into the distal part of the ileum (biliary pancreatic diversion).
In biliopancreatic diversion (BPD), the lower and middle third of the stomach is 
resected leaving a small gastric pouch. The upper end of the duodenum is closed. 
The distal jejunum is divided. The distal end of the jejunum is then anastomosed 
to the gastric pouch. The proximal end of the jejunum is then anastomosed to the 
distal ileum forming a short common channel in which biliary and pancreatic 
juices mix with food prior to proceeding into the colon [13].
3. Hybrid procedures: There is combination of restriction of food intake and mal-
absorption of food. The typical example is Roux-en-Y gastric bypass (RYGB). 
This procedure divides the upper part of the stomach to create a small gastric 
pouch with a capacity of 20–30 ml (Figure 5). The proximal jejunum is divided 
50 cm beyond the ligament of Treitz. The distal jejunal end is then connected 
to the gastric pouch. The proximal jejunal end of the small bowel is sutured 
to the jejunum (75–150 cm from the gastric pouch) to form the so-called 
Roux-en-Y reconstruction. The small gastric pouch (restrictive component) 
causes early satiety and helps in decreasing food intake. The Roux or alimen-
tary limb (typically 75–150 cm long) extends from the gastric pouch to the 
Figure 4. 
Biliopancreatic diversion (BPD).
5Non-alcoholic Fatty Liver Disease and Surgery
DOI: http://dx.doi.org/10.5772/intechopen.86146
jejunojejunostomy site and carries ingested food. The proximal biliopancreatic 
limb (30–60 cm long) containing excluded stomach, duodenum, and proximal 
jejunum transfers biliary and pancreatic secretions to the jejunojejunostomy 
site. Most of the digestion and absorption occur in the common channel which 
extends from the jejunojejunostomy site to the ileocecal valve.
A schematic diagram of different bariatric surgeries is shown below.
2. Benefits and risks of bariatric surgery on NAFLD
Sleeve gastrectomy: Different studies were done to find out the effect of sleeve 
gastrectomy on NAFLD. Algooneh et al. observed that 56% of total 84 transabdom-
inal ultrasonographically diagnosed NAFLD patients showed complete resolution 
of hepatic steatosis 3.3 years (average) after isolated sleeve gastrectomy [14]. Karcz 
et al. found that there was significant reduction (>50%) of transaminases in NASH 
patients within 6 months of isolated sleeve gastrectomy [15]. Parveen-Raj et al. 
did a prospective observational trial and found that surgically induced weight loss 
improved NAFLD histology significantly 6 months after isolated sleeve gastrectomy 
in morbidly obese patients [16].
LAGB: There have been several studies showing the effects of LAGB on 
NAFLD. Most of the studies reported improvement of hepatic steatosis, steatohepa-
titis, and fibrosis, but some studies showed mild increase in fibrosis.
Few LAGB studies with their effects on NAFLD are mentioned in Table 1.
Biliopancreatic diversion (BPD) and biliopancreatic diversion with duodenal 
switch (BPD with DS): Both procedures produce long-term malabsorption and 
severe weight loss. They are not widely done. Their effects on NAFLD are summa-
rized in two studies in Table 2.
In patients with BPD with DS, the transient deterioration of transaminases 
and steatohepatitis seen in the first 6 months postoperatively was possibly due to 
rapid weight loss. Transaminases became normalized by 12 months. Then there 
Figure 5. 
RYGB.
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Study Type of 
surgery
Outcome Sample 
size
Follow-up
Keshishian 
et al. [24]
BPD with 
DS
Transaminases and NASH worsened 
at 6 months Steatosis and NASH 
decreased after 6 months
78 36 months
Kral et al. [25] BPD Severe fibrosis decreased in 27% 
and mild fibrosis appeared in 40%: 
41 ± 25 months after BPD
104 41 ± 25 months
Table 2. 
Summary of effects of BPD and BPD with DS on NAFLD.
Study Outcome Sample size Follow-up
Luyckx et al. [17] ↓ Steatosis
↑ Mild hepatitis
69 27 ± 15 months
Busetto et al. [18] ↓ Steatosis 6 24 weeks
Stratopoulas et al. [19] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
51 17 months
Jaskiewicz et al. [20] ↓ Steatosis
↓ Steatohepatitis
87 41 months
Phillips et al. [21] ↓ Steatosis
↓ Gamma-glutamyl 
transferase
29 3 months
Dixon et al. [22] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
60 29.5 ± 10 months
Mathurin et al. [23] ↓ Steatosis
↓ Fibrosis
381 60 months
Table 1. 
Summary of LAGB studies showing effects on NAFLD.
Study Outcome Sample size Follow-up
Mottin et al. [26] ↓ Steatosis 90 12 months
Matter et al. [27] ↓ Steatosis
↓ Fibrosis
90 12 months
Clark et al. [28] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
16 305 ± 131 days
Silverman et al. [29] ↓ Steatosis
↓ Fibrosis
91 18.4 months
Lie et al. [30] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
39 18 months
Barker et al. [31] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
19 21.4 months
Klein et al. [32] ↓ Steatosis 7 12 months
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was progressive improvement of steatosis and steatohepatitis up to 3 years. In 
patients who had BPD, the appearance of mild fibrosis was possibly related to 
severe diarrhea, hypoalbuminemia, some intake of alcohol, and postmenopausal 
status.
Roux-en-Y gastric bypass (RYGB): Effects of RYGB have been studied exten-
sively in different studies. Most of the studies showed improvement of steatosis, 
steatohepatitis, and hepatic fibrosis. Summary of some of the RYGB studies are 
mentioned in Table 3.
3. How does bariatric surgery help NAFLD?
1. By achieving weight loss: Weight loss is the key in the treatment of NAFLD 
[36]. Seven to ten percent of weight loss by lifestyle modification has been 
shown to improve hepatic steatosis and steatohepatitis [37]. Significant and 
sustained weight loss is common after bariatric surgery.
2. By improving insulin resistance: Obesity is associated with insulin resistance, 
i.e., insulin receptors fail to work. How does this happen? Adipose tissue works 
as a metabolically active endocrine organ and produces proinflammatory 
cytokines—TNF-α, IL-1, IL-6, IL-8, IL-18, and C-reactive protein [38]. In 
obesity, excessive production of these cytokines occurs leading to a proinflam-
matory state which is associated with insulin resistance. Adiponectin is a fat 
cell hormone produced in the white adipose tissue. It plays an important role 
in the regulation of glucose and fat metabolism in insulin-sensitive tissues. It 
increases fatty acid oxidation and decreases de novo synthesis of fatty acid. 
In diet-induced obesity, the circulating level of adiponectin is paradoxically 
decreased [39]. Hypoadiponectinemia in obesity is associated with insulin 
resistance [40]. In obesity, excessive intraperitoneal fat promotes free fatty 
acid (FFA) reflux directly into the hepatocytes via the portal vein [41]. FFA 
metabolites (long-chain acyl-CoAs and diacylglycerol) then transfer cyto-
plasmic protein kinase Cs to the cell membrane. Subsequently, intracellular 
portions of insulin receptors are phosphorylated by protein kinase C leading to 
insulin resistance.
As a result of insulin resistance, lipolysis occurs in the adipose tissue with 
increased levels of plasma FFA and excessive influx of FFA into the hepatocytes. 
In the hepatocytes, fatty acid oxidation is inhibited, and de novo synthesis of 
fatty acid occurs leading to triglyceride synthesis and hepatic steatosis.
Study Outcome Sample size Follow-up
Furuya et al. [33] ↓ Steatosis
↓ Fibrosis
18 24 months
Weiner et al. [34] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
116 18.6 ± 8.3 months
De Almeida et al. [35] ↓ Steatosis
↓ Steatohepatitis
↓ Fibrosis
16 23.5 ± 8.4 months
Table 3. 
Summary of effects of RYGB on NAFLD.
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Bariatric surgery reduces insulin resistance by decreasing production of proin-
flammatory cytokines and improving the adiponectin level.
3. By improving dyslipidemia: NAFLD is associated with increased levels of 
serum triglyceride (TG) and low-density lipoprotein (LDL) and decreased 
level of high-density lipoprotein (HDL). As they are the main risk factors for 
the development atherosclerosis and coronary artery disease, cardiovascular 
disease is the main cause of mortality in NAFLD patients [42]. Bariatric 
surgery significantly improves the dyslipidemic state, and most of the patients 
do not need anymore lipid-lowering agents [43].
4. By improving the metabolic hormone profile: Gastrointestinal hormones play 
important roles in the success of weight loss and thus improve manifestations 
of metabolic syndrome following bariatric surgery. Ghrelin is the hunger 
hormone (orexigenic) mainly produced in oxyntic glands of gastric fundus 
[44]. Ghrelin also increases gastrointestinal motility and decreases insulin 
secretion [45]. In patients with Roux-en-Y gastric bypass, sleeve gastrectomy, 
and BPD with DS, ghrelin levels are profoundly low, and this may explain loss 
of hunger sensation and rapid weight loss in these patients [46, 47]. Glucagon-
like peptide-1 (GLP-1) is secreted by the L cells in the distal ileum and colon. 
It promotes glucose-dependent insulin secretion, inhibits glucagon secretion, 
delays gastric emptying, inhibits gastric acid secretion, and reduces hunger 
sensation. Peptide tyrosine-tyrosine (PYY) is co-secreted with GLP-1 by the 
L cells of the distal ileum and colon after ingestion of food. It reduces hunger 
[48], delays gastric emptying, and decreases gastric acid secretion [49]. Serum 
levels of GLP-1 and PYY are high in post-RYGB patients because of rapid 
delivery of nutrients to the distal gut. As a result, the post-RYGB patients 
experience early satiety, their blood glucose and triglyceride levels decrease, 
and HDL level increases. The metabolic improvement can be seen as early as 
2 days after surgery and do not correlate with the degree of weight loss. Many 
patients’ diabetes mellitus, hypertension, and dyslipidemia either disappear 
or get under control. The improvement of components of metabolic syndrome 
has positive effects on NAFLD.
4. Bariatric surgery and cirrhosis of the liver
Bariatric surgery carries an increased risk of morbidity and mortality in patients 
with cirrhosis of the liver due to NAFLD. Risk assessment should be done by 
evaluating the severity of liver disease and presence of hepatic reserve. The Child-
Turcotte-Pugh (CTP) score and the Model for End-Stage Liver Disease (MELD) 
score can predict postoperative mortality. The presence of portal hypertension 
(HVPG >10 mm Hg) indicates worse outcome. Clinically patients may have gas-
troesophageal varices, ascites, and splenomegaly with thrombocytopenia [50]. 
Transjugular intrahepatic portosystemic shunt (TIPS) placement is an option 
for these patients to reduce postoperative complications [51]. There has been no 
randomized clinical trial of doing bariatric surgery on cirrhotic patients due to 
NAFLD. Most of the studies were done on unsuspected compensated cirrhotic 
patients. Brolin et al. published a study in 1998 on unsuspected cirrhotic patients 
discovered during surgery. Four percent of patients died in the perioperative 
period, and 8% died late due to liver disease [52]. Mosko et al. reviewed nationwide 
data collection of patients who had bariatric surgery in the United States between 
1998 and 2007 [53]. Non-cirrhotic patients had less mortality and shorter length 
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of hospital stay in comparison with compensated and decompensated cirrhotic 
patients (mortality 0.3 vs. 0.9 and 16.3%, respectively, and length of stay 3.2 vs. 
4.4 and 6.7 days, respectively). The study also found that high-volume centers 
(performing >100 surgeries per year) had lower mortality rate (0.2 vs. 0.7%; 
p < 0.0001) than low volume centers (performing <50 surgeries per year). Shimizu 
et al. did a study on 22 Child’s A and 1 Child’s B cirrhotic patients who underwent 
laparoscopic RYGB, laparoscopic sleeve gastrectomy, and LAGB between 2004 and 
2011. No patient had decompensation of liver disease after surgery [54]. Pestana 
et al. did a retrospective review on 14 Child’s A cirrhotic patients (4 with portal 
hypertension and 10 without portal hypertension) who had bariatric surgeries 
(sleeve gastrectomy and gastric bypass) between 2009 and 2011. Significant weight 
loss with improvement of hepatic steatosis, diabetes mellitus, hypertension, and 
dyslipidemia occurred. None of them had peri- or postoperative surgical complica-
tions or bleeding [55].
From the above studies, it is apparent that bariatric surgeries can be safely per-
formed in high-volume centers with acceptable morbidity and mortality in carefully 
selected compensated cirrhotic patients. The next question comes: What type of 
bariatric surgery is suitable for cirrhotic patients? Currently, three types of bariatric 
surgery are most commonly done. These include laparoscopic RYGB, laparoscopic 
sleeve gastrectomy, and LAGB. Each type has its own pros and cons which are 
mentioned in Table 4.
Modality of gastric bypass surgery should be individualized according to 
patients’ comorbidities and pros and cons of each type of surgery. Sleeve gastrec-
tomy is becoming more popular. Although bariatric surgery poses significant risks 
to patients with cirrhosis due to NAFLD, the considerable benefits of significant 
Type of 
surgery
Pros Cons
Laparoscopic 
RYGB
Most significant weight loss out 
of the three procedures
1. Endoscopic access to the excluded stomach 
is difficult if there is a need to deal with 
gastroduodenal bleeding, biliary obstruction, 
pancreatic mass, or cyst when patients may 
need laparoscopic gastroduodenoscopy [56] or 
EUS-guided transgastric access for ERCP and 
EUS/FNA [57, 58]
2. Malabsorption of micronutrients and vitamin 
may cause progressive liver dysfunction
3. Alteration of anatomy may complicate future 
liver transplantation
LAGB Least invasive procedure out of 
the three
Foreign device implantation may cause infection, 
particularly in the presence of ascites Currently 
contraindicated by the FDA to be placed in 
cirrhosis of the liver [59]
Laparoscopic 
sleeve 
gastrectomy
4. Technically less challenging 
to the surgeon with short 
operating time
5. Does not cause malabsorp-
tion of micronutrients and 
vitamins
6. No requirement of foreign 
device implantation
Risk of significant bleeding in patients with 
gastric varices
EUS, endoscopic ultrasound; ERCP, endoscopic retrograde cholangiopancreatography; FNA, fine needle aspiration.
Table 4. 
Pros and cons of different types of bariatric surgery in cirrhosis of the liver.
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weight loss (including decreasing the risk of cardiovascular diseases and malig-
nancy) and candidacy for liver transplantation may overweigh the risks. The 
AASLD guidelines published in January 2018 do not recommend bariatric surgery 
to patients with cirrhosis of the liver attributed to NAFLD as the type, safety, and 
efficacy of bariatric surgery are not yet established in this group of patients [60].
5. Bariatric surgery and orthotopic liver transplantation
Some transplant centers have a strict criteria of not performing orthotopic 
liver transplantation with BMI > 35. Orthotopic liver transplantation in morbidly 
obese patients is technically difficult and can be associated with increased bleed-
ing, postoperative complications, morbidity, and mortality [61]. The longevity 
of morbidly obese transplanted patients is also shortened. Pretransplant bariatric 
surgery is considered in these patients to reach the BMI goal for liver transplanta-
tion. Lin et al. did a retrospective study in pretransplant morbidly obese patients 
and found that laparoscopic sleeve gastrectomy was safe and successful in causing 
significant weight loss and improving candidacy for liver transplantation [62]. On 
the other hand, one third of post-liver transplant patients become obese, and some 
of them become morbidly obese due to increased appetite, increased calorie intake, 
sedentary lifestyle, and corticosteroid therapy. A proportion of these patients may 
develop metabolic syndrome and NAFLD in the transplanted liver. Both RYGB and 
laparoscopic sleeve gastrectomy have been found to be safe and feasible in post-liver 
transplant morbidly obese patients [63, 64]. Another small study showed combined 
liver transplantation and sleeve gastrectomy in morbidly obese patients led to effec-
tive weight loss and less metabolic complications. There was no mortality or graft 
loss in those patients [65]. So bariatric surgery has been found to be safe before, 
during, and after liver transplantation in selected patients in small studies although 
there is no consensus about the optimal timing yet.
6. Conclusion
With the epidemic of obesity, there will be steep rise in performing bariatric 
surgery on NAFLD patients. Multiple cohort studies suggest that bariatric surger-
ies are extremely effective in lowering significant amount of body weight and in 
improving the metabolic syndrome and histology of NAFLD. Bariatric surgery 
helps NAFLD in achieving significant and durable weight loss, decreasing insulin 
resistance, ameliorating dyslipidemia, and improving metabolic hormone pro-
file. As most of the patients with NAFLD die from cardiovascular diseases and 
malignancy, bariatric surgery should be considered in otherwise obese individuals 
with NAFLD. The commonly used bariatric surgeries include laparoscopic RYGB, 
laparoscopic sleeve gastrectomy, and LAGB. According to cohort studies, bariatric 
surgeries can be performed safely in patients with compensated Child’s A cirrhosis 
attributed to NAFLD. But at the present time, AASLD does not recommend bar-
iatric surgery in patients with cirrhosis attributed to NAFLD because of the lack 
of randomized controlled trial. Prospective randomized controlled trials are also 
needed in morbidly obese patients with end-stage liver disease attributed to NAFLD 
to find out whether performing simultaneous orthotopic liver transplantation and 
bariatric surgery are safe and effective.
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